Neubase TherapeuticsNBSE
13F holders, Q1 2024 (March 31)18holders
3famous investors
$0.45avg. 13F price*
At the end of Q1 2024, 18 institutions reported holding Neubase Therapeutics Inc. (NBSE) in their 13F filings. The largest holders were Greenlight Capital (DME Capital Management) ($61K), Renaissance Technologies ($40K) and Point72 Asset Management ($28K). 3 famous investors held it, including David Einhorn (0.0% of Greenlight Capital (DME Capital Management)'s portfolio), Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Steve Cohen (0.0% of Point72 Asset Management's portfolio).
- Company
- Neubase Therapeutics Inc.
- CUSIP
- 64132K201
- Latest filing quarter
- Q2 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $563 |
| Exits | 4 | $28K |
Ownership 18 holders
| Greenlight Capital (DME Capital Management) | 0.00% | No change | 136,350 | $61K |
| Renaissance Technologies | 0.00% | Add +54.9% | 88,229 | $40K |
| Point72 Asset Management | 0.00% | No change | 62,500 | $28K |
| Carnegie Mellon University | 0.03% | No change | 46,970 | $21K |
| Vanguard Group Inc. | 0.00% | No change | 18,981 | $9K |
| Prelude Capital Management, LLC | 0.00% | No change | 15,550 | $7K |
| Geode Capital Management, LLC | 0.00% | No change | 15,482 | $7K |
| UBS Group AG | 0.00% | Reduce -93.8% | 4,056 | $2K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +5.1% | 2,572 | $1K |
| Cubist Systematic Strategies, LLC | 0.00% | New | 1,251 | $563 |
| Bank of America Corp. | 0.00% | No change | 804 | $361 |
| First Manhattan Co. Llc. | 0.00% | No change | 353 | $158 |
| Wells Fargo & Company | 0.00% | No change | 79 | $35 |
| Osaic Holdings, Inc. | 0.00% | No change | 22 | $10 |
| PNC Financial Services Group, Inc. | 0.00% | No change | 21 | $9 |
| NFSG Corp | 0.00% | No change | 12 | $5 |
| Morgan Stanley | 0.00% | No change | 9 | $4 |
| Royal Bank of Canada | 0.00% | Reduce -49.0% | 153 | $0 |
"% of holder's portfolio" is NBSE's weight in each manager's 13F, not the share of Neubase Therapeutics Inc. the manager owns.